Project Grant R01AI201564
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $149,190 to the University of Massachusetts Medical School on December 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project grant (F31AI191745) to investigate hemagglutinin-mediated molecular mechanisms of avian influenza A virus host tropism. The research examines how the hemagglutinin (HA)...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $434,938 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanobodies as therapeutic agents against H5N1 influenza virus. The project develops potent, broadly neutralizing anti-H5N1 nanobodies with high stability and rapid production capability, engineered for efficient aerosol delivery to the lungs. The research targets the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pennsylvania $662,804 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate H5N1 transmission and spillover risk across North America through three integrated research aims. The funded work addresses ecological and evolutionary factors governing H5N1 dynamics in wild bird populations. Aim 1 comprises the first comprehensive assessment of H5N1 reassortment in...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded The Washington University $765,798 on September 3, 2026, to develop a mucosal H5 influenza virus vaccine under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop a single-dose mucosal vaccine using a chimpanzee adenovirus vectored platform to confer robust protection against high-dose H5N1 challenge and transmission in pre-clinical...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $233,118 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the mechanistic rules governing respiratory virus transmission through integrated analysis of ferret contact patterns and viral dynamics. The project addresses gaps in understanding influenza A virus transmission routes—contact, droplet, airborne, and fomite—by combining video datasets from controlled...
- Federal Grant Award Summary Emory University received a $2,297,892 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 17, 2025, with completion targeted for June 30, 2029. The award funds a four-year research investigation into the mechanisms by which interferon-induced transmembrane proteins (IFITMs) inhibit viral membrane fusion and restrict diverse enveloped viruses...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $703,187 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI201207) to advance understanding of antigenically complex hemagglutinin vaccine formulation requirements and mechanisms of protection in universal influenza vaccine development. The research addresses a core limitation of current influenza vaccines: they induce responses primarily against...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cross-protective immune mechanisms of combined mRNA and conventional influenza vaccines. The research develops new mRNA vaccine constructs encoding neuraminidase conjugated to a conserved M2E repeat, designed to enhance broad cross-protection against different...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- Federal Grant Award Summary Emory University received a $160,546.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 3, 2025, through August 31, 2029. The project, titled "Towards Foundation Epidemic Models for Respiratory Infections: A Novel Spatiotemporal Machine Learning Framework," will be conducted at Emory's Atlanta, Georgia campus. This award...
The National Institute of Allergy and Infectious Diseases awarded Emory University $3,094,830 under Project Grant R01AI201564 on September 1, 2026, to investigate reassortment of highly pathogenic avian influenza viruses and its effects on viral fitness and host range adaptation. The award funds research examining how H5N1 clade 2.3.4.4B viruses exchange genetic segments with low-pathogenicity avian influenza viruses and human-adapted influenza viruses, with particular focus on assessing pandemic risk through species-specific organoid models derived from avian and mammalian hosts. The research addresses the ecological shift in H5N1 toward increased mammalian infection and aims to elucidate molecular drivers of cross-species transmission. Performance occurs at Emory University in Atlanta, Georgia from September 1, 2026 through August 31, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855), a competitive research grant mechanism supporting biomedical research and research training in infectious diseases at public and private nonprofit institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.1m | 8/11/26 |